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Peptide-based vaccines offer several advantages over conventional whole organism or pro-
tein approaches by offering improved purity and specificity in inducing immune response.
However, peptides alone are generally non-immunogenic. Concerns remain about the tox-
icity of adjuvants which are critical for immunogenicity of synthetic peptides. The use
of lipopeptides in peptide vaccines is currently under intensive investigation because
potent immune responses can be generated without the use of adjuvant (thus are self-
adjuvanting). Several lipopeptides derived from microbial origin, and their synthetic versions
or simpler fatty acid moieties impart this self-adjuvanting activity by signaling via Toll-like
receptor 2 (TLR2). Engagement of this innate immune receptor on antigen-presenting
cell leads to the initiation and development of potent immune responses. Therefore opti-
mization of lipopeptides to enhance TLR2-mediated activation is a promising strategy for
vaccine development. Considerable structure-activity relationships that determine TLR2
binding and consequent stimulation of innate immune responses have been investigated
for a range of lipopeptides. In this mini review we address the development of lipopeptide
vaccines, mechanism ofTLR2 recognition, and immune activation. An overview is provided
of the best studied lipopeptide vaccine systems.
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INTRODUCTION
The immune system functions to defend against invasion by
pathogens. Vaccination is predominantly a preventive measure
that aims to build specific immune defenses (antibodies or cel-
lular) to protect an individual against infection. Traditional vac-
cine formulations are based on whole (inactivated or killed)
pathogens or pathogen-specific proteins. While this model of vac-
cine has been successful for preventing some infectious diseases,
many pathogens cannot be targeted using this approach. Prob-
lems include undesirable host reactions, reversion to virulence,
and the inability to efficiently culture the pathogen. Logistical
problems faced by traditional vaccines include the necessity to
maintain a cold chain: an uninterrupted series of refrigerated
storage, transport, and distribution (1).
Subunit vaccines based on short, specific fragments of a
pathogen provide a rational and attractive alternative to traditional
vaccine design (Figure 1). Rational vaccine design are composed
of antigen(s), delivery systems, and adjuvant that induce immune
responses against specific epitopes to protect against a pathogen
(2). These vaccines are safer as they are non-infectious and more
immunologically defined than traditional approaches. Synthetic
peptides have received considerable interest as a basis for subunit
vaccine design. Peptide subunit vaccines are generally composed of
30–60 amino acids representing the antigen/s of interest. Peptide/s
that represent the minimal component of a protein against which
an immune response is desired enables more precise selection of
vaccine components, allowing for specificity of immune responses.
Peptides are directly involved in the extent and specificity of cel-
lular (T cells) and humoral (antibody) immune responses as this
is generally mediated through the recognition of peptides repre-
senting B cell receptor (BCR) and T cell receptor (TCR) epitopes
(2). Therefore, delivering pathogen-derived peptides that are B
and/or T cell receptor epitopes represents an effective way induce
an immune response. Furthermore, peptides can easily be synthe-
sized and characterized and are generally more stable than whole
pathogens or proteins. Studies have shown peptide-based vaccine
candidates to be effective following ambient temperature storage
(3). This lowers the need to maintain a cold chain, which is of
significance particularly in developing countries that lack expen-
sive refrigeration capability. This combination of generating an
effective, specific immunity, and providing an economical alterna-
tive to current vaccination programs makes subunit peptide-based
vaccine development highly promising.
Although representing promising vaccine candidates, peptides
are often poorly immunogenic when used alone as vaccines. This is
due to the lack of pathogen-derived molecules to act as danger sig-
nals that are required for efficient activation of the innate immune
system, which consequently leads to lack of an adaptive immune
response. Peptide-based vaccines require additional adjuvants to
be effective. Adjuvants are defined as any agent that can increase
the immunostimulatory effect of an antigen. In this review, after
briefly introducing the key immunological interaction between
vaccines and the immune system, the latest developments in the
design of lipopeptide-based vaccines will be discussed.
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FIGURE 1 | Subunit vaccines. An alternative to inactivated or attenuated whole pathogen vaccines. Comprised of fragment/s of the microorganism to generate
a protective immune response.
MAIN IMMUNOLOGICAL CONCEPTS OF VACCINE
DEVELOPMENT
Adaptive immunity is based on two components, one responsi-
ble for the cytotoxic immune response (cellular) the other for
generating the humoral (antibody) immune response. The three
main cells [B cells, T cells, and dendritic cells (DCs)] involved in
inducing an immune response are summarized in Figure 2. The
is “adaptive” immune response is named as such as it provides the
host with the ability to identify and memorize specific pathogens
(to generate immunity) and to mount a more effective response
when the pathogen is re-encountered. This mechanism allows a
small number of genes to generate a vast number of different anti-
gen receptors and the propagation of memory B cells and T cells
that are the essential to long-term pathogen-specific immunity.
This is also known as immunological memory. It is the memory
cells form a pool of effective B and T cells and upon interaction
with a previously encountered antigen, the appropriate memory
cells are selected and activated.
Cytotoxic T lymphocytes (CTLs; also called CD8+ T cells)
exert cytotoxic action on infected or tumor cells. Humoral
immune responses are based on B cells which generate antibodies
against pathogen-specific components. Both cellular and humoral
immune responses require T-helper cells (TH cells; also called
CD4+ T cells) (4). TH cells have an important role in adaptive
immunity: through release of cytokines they mediate B cell anti-
body class switching and activation and proliferation of CTLs (5,
6). TH cells have been further subdivided into TH1 or TH2 lineage
according to their cytokine profiles. TH1 cells are associated with
enhancing clearance of intracellular pathogens and are defined on
the basis of their production of the cytokine interferon-gamma
(IFN-γ) (7). TH2 cells are essential for the control of certain
parasitic infections and mediate host defense against extracellu-
lar parasites through the production of interleukin 4 (IL-4), IL-5,
and IL-13.
Cytotoxic T lymphocytes recognize infected or cancerous cells
through recognition peptides from within the cell. These pep-
tides are displayed on major histocompatibility complex class I
(MHC class I) molecules. Presentation of appropriate peptide epi-
topes on MHC class I molecules by specialized antigen-presenting
cells (APCs), such as DCs and macrophages, results in a cellular
response. TH cells recognize peptides derived from extracellular
FIGURE 2 | Cells of the immune system. Lymph nodes present along the
lymphatic vessels contain specialized compartments where immune cells
collect and encounter antigens. B, T, dendritic cells, and other immune cells
are present, thus can mount an effective and appropriate immune response.
proteins displayed on MHC class II molecules on APCs. Recog-
nition by receptors on TH cells the MHC class II bound peptides
allows interaction with the APC. Additional interactions occur
through co-stimulatory molecules that are expressed on APCs and
their ligands on the TH-cell. These events, known as activation sig-
nals, allow the TH-cell to respond to B cells that have taken up and
display the same peptide/MHC II complexes. It is this interaction
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FIGURE 3 | Induction of an immune response. Antigen is taken
up by antigen-presenting cells (e.g., DCs), in the presence of
immunostimulatory molecules, resulting in DC maturation. This
maturation process involves processing of antigen to display peptide
epitopes on MHC class molecules alongside co-stimulatory
molecules to T cells. Subtypes of T cells that recognize the
peptide-epitope then mediate an antigen-specific cellular or humoral
immune response.
between TH cells and B cells that result in differentiation of B cells
into plasma cells that secrete antigen-specific antibodies. Some
cytokine signals sent by TH cells stimulate CTLs. In both cel-
lular and humoral responses, the TCR on the surface CTL and
TH-cell associates with the MHC I/peptide-epitope or the MHC
II/peptide-epitope respectively. This peptide dependent recogni-
tion processes results in propagation of immune responses that
control extracellular/intracellular infection. This is represented in
Figure 3. The goal of vaccination is to induce protective immunity
by stimulating antigen-specific CTLs or B cells with the help of TH
cells. Therefore, vaccine components must contain two antigenic
epitopes: a TH epitope and an antigen to elicit an antigen-specific
B cell or CTL response, as desired.
ADJUVANTS FOR PEPTIDE-BASED VACCINES
In addition to the selected B or CTL epitopes and TH-cell epitopes,
peptide-based vaccines require an adjuvant to be immunogenic.
Adjuvants can activate the immune system in a variety of ways:
protecting antigen from rapid degradation; providing an anti-
gen depot which allows antigen sampling by APCs for a longer
time before clearance; by activating pattern recognition receptors
(PRRs) on APCs which recognize pathogen-associated molecular
patterns (PAMPs). Although numerous vaccine adjuvants have
been reported, few have been approved for human use. Adju-
vants licensed for human use include alum, monophosphoryl lipid
A (MPL), virus-like particles, and immunopotentiating reconsti-
tuted influenza virosomes (IRIV) (1). In Europe, MF59 and AS03
(oil-in-water emulsions) are licensed for use for influenza vaccines
(1). AS04, a combination of MPL and alum, is approved for hepati-
tis B virus (HBV) and human papillomavirus (HPV) vaccines in
Europe and the USA (1). Adjuvants licensed for human use are
listed in Table 1. Many of the aforementioned adjuvants approved
for human use are unsuitable for peptide vaccines. Recent advances
in development of adjuvants, including agonists for PRRs have
made peptide-based vaccines a promising option for development
of modern vaccines.
TOLL-LIKE RECEPTORS
Toll-like receptors (TLRs) are the most thoroughly characterized
PRR which are expressed on variety of cells including B cells
(9), CD4+ T cell subsets (10), monocytes (11), APCs (DCs, and
macrophages) (12), and certain types of epithelial cells (13). TLR
expression patterns on these cells can vary. Most TLR ligands are
microbial products (representing PAMPs) that signal the presence
of an infection to the host. TLR-mediated stimulation of APCs sig-
nificantly enhances the secretion of pro-inflammatory cytokines,
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Table 1 | Adjuvants licensed for human use including the year licensed and the propieratory company, composition and use in relevant
vaccines (8).
Name Composition Vaccine
Alum (1924) Aluminum phosphate or aluminum hydroxide Numerous
MF59 (Novartis, 1997) Squalene, polysorbate 80, sorbitan trioleate Seasonal, pandemic, and pre-pandemic influenza
AS03 (GlaxoSmithKline, 2009) Squalene, tween 80, α-tocopherol Pandemic and pre-pandemic influenza
Virosomes (Berna Biotech, 2000) Lipids, hemagglutinin Seasonal influenza, hepatitis A
AS04 (GlaxoSmithKline, 2005) Aluminum hydroxide, MPL Hepatitis B, human papilloma virus
FIGURE 4 |Toll-like receptor signaling pathway: recognition of
pathogens throughTLR ultimately triggers signaling through the
NF-κB pathway, consequently leading to gene activation and
production of pro-inflammatory cytokines/chemokines.
antibody production, and immune responses. TLRs are evolution-
arily conserved proteins, characterized by an extracellular leucine-
rich repeat domain and an intracellular Toll/IL-1 receptor-like
(TIR) domain (1). TLRs utilize activation of intracellular adap-
tor molecules and kinases to induce an inflammatory response (1).
The transcription factor NF-κB is a key regulator of the expression
of pro-inflammatory mediators that leads to an immune response
(2). Numerous genes with roles in immunity and inflammation
are regulated by NF-κB. Associating the TIR domain of the adap-
tor molecule MyD88 with the TIR domain of TLRs is needed
for signaling to NF-κB/mitogen-activated protein kinase pathways
Figure 4 (6, 14). This consequently results in MyD88 engaging IL-1
receptor-associated kinase,which then induces activation of tumor
necrosis factor receptor-associated factor 6, NF-κB, and mitogen-
activated protein kinases (6). Although MyD88 is a universal
adaptor protein for all TLRs (5), studies revealed the existence
of four other adaptor proteins named MAL, TRIF, TRAM, and
SARM which can be used in a TLR-specific way (3, 6, 15, 16).
A basic overview of the TLR signaling pathway is provided in
Figure 4.
Ten human and 12 murine TLRs have been identified, TLR1-10
in humans, and TLR1-9 and TLR11-13 in mice (17). Mouse TLR10
is a pseudogene because only a partial (non-functional) genomic
sequence has been detected and it is not expressed (18). TLR
PAMPs include: bacterial cell-wall components, e.g., lipopolysac-
charide (LPS) (19), peptidoglycan (20), and lipopeptides (21);
flagellin (22); bacterial DNA (23); and viral RNA (24). Many
of the TLR ligands were originally identified through screening
of PAMPs in human embryonal kidney HEK293 cells transiently
transfected with TLRs (25–27). HEK293 T cells present a valu-
able model for these studies as they do not naturally express any
TLRs (25, 28). From 1999 onward, Akira and colleagues have
generated multiple TLR and adaptor molecule-knockout mice
(29). This has been invaluable for defining in vivo specific lig-
ands for each TLR and defining the important roles of TLRs in
immunity.
The use of synthetic peptides for vaccine development has been
hampered by problems such as need for an adjuvant. The incor-
poration of lipopeptides as a strategy to enhance immunogenicity
has been ongoing since the early 1980s. The following sections
expand on the development of lipopeptides as vaccines and their
TLR2-targeting ability as the basis for their immunogenicity.
TLR2 AND LIPOPEPTIDES
A membrane surface receptor, TLR2 recognizes many bacterial,
fungal, and viral molecules. Generally this result in the uptake of
TLR2 bound molecules and cellular activation of APCs (30–32).
TLR2 recognizes lipoteichoic acid (33–35), zymosan (36, 37), and
bacterial lipoproteins (38–40). TLR2 has also been reported to rec-
ognized peptidoglycan (41, 42), however this sensing was lost after
the removal of lipoproteins or lipoteichoic acids (43).
The selection of TLR2-targeting adjuvants for peptide vaccines
has focused on bacterial lipopeptides and their synthetic analogs
(Figure 5). These are common bacterial cell-wall components. A
number of bacterial species produce lipopeptides that have impor-
tant biological functions (44). They generally consist of short
structures of amino acids linked to fatty acids via ester or amide
bonds. Gram-positive bacterial lipoproteins contain two fatty acid
chains compared to three in Gram-negative lipoproteins. The acyl
chains are heterogeneous in terms of their length and degree of
saturation, however most frequently they are palmitic acid (con-
taining 16 carbons). Identification of the number of acyl chains
involves the formation of heterodimers with TLR6 or TLR1 with
TLR2. Heterodimers with TLR1 enables TLR2 to identify triacyl
lipoproteins or lipopeptides whilst heterodimerization of TLR2
Frontiers in Immunology | Microbial Immunology October 2013 | Volume 4 | Article 318 | 4
Zaman and Toth Structure-activity of lipopeptide vaccines
and 6 is involved in the detection of diacyl lipopeptides (45).
However signaling through TLR2 alone has also been reported
for some lipopeptides (46).
Inherent properties of lipopeptides such as surfactant, antibac-
terial and/or antifungal activity have attracted considerable scien-
tific, therapeutic, and biotechnological interests (47). Lipopeptides
have been used in the pharmaceutical industry against bacteria and
fungi (48, 49). In cosmetics, the surfactant and anti-wrinkle char-
acteristics of lipopeptides are often included in skin care products
(50). In the food industry, lipopeptides are used as emulsifiers
in various food products (47). Lipopeptides have also been used
in biotechnology as biosurfactants, with industrial and medical
applications (51–53).
Lipopeptides function to confer a competitive advantage in
interactions with other microorganisms by exhibiting lytic and
growth-inhibitory activities against a broad range of microorgan-
isms (49, 54), protect against predators (55), allow movement
of bacteria across surfaces (56), and enable attachment to sur-
faces (57). The use of lipopeptides in peptide-based vaccines
is derived from the seminal work of Hopp and co-workers in
the 1980s which found a significant improvement in antigen-
specific antibody response was obtained when a hepatitis virus
peptide epitopes was conjugated to a dipalmitoyl-lysine moiety
(58). In addition, lipopeptides are well suited to the development
of peptide-based vaccines, because they can be easily conjugated
to or synthesized during solid-phase peptide synthesis to peptide
antigens to generate a highly pure, chemically defined vaccine (59).
Before the discovery of TLRs and their role in lipopeptide
recognition, the underlying mechanisms by which lipopeptides
elicited an immune response were only partially understood (60).
Among several hypotheses, including prevention of enzymatic
peptide degradation, it was highlighted that the palmitoyl moi-
ety of lipopeptides may be able to attach and then fuse to APC
cell membranes and subsequently deliver peptide epitopes into
the APCs (60, 61).
Understanding the mechanism of lipopeptide immunostimu-
latory activity has motivated research into lipopeptide structure –
activity relationships for the development of lipopeptide vaccines.
The following section describes the main lipid moieties used and
their structure-activity relationships.
Pam3Cys AND Pam2Cys
Braun’s lipoprotein from Escherichia coli (E. coli) was identified
in the cell-wall of Gram-negative bacteria. The synthetic ana-
log, Tripalmitoyl-S-glyceryl-cysteine (Pam3Cys) (Figure 5A), was
engineered to enhance the immunogenicity of epitopes derived
from influenza virus and enhance virus-specific CTLs when mice
were injected with an MHC class I epitope conjugated to Pam3Cys
(62–64). Pam3Cys is comprised of three palmitic acid groups
that are bound in an ester and amide linkage to a cysteine
residue.
This lipid moiety has been studied extensively for the devel-
opment of peptide vaccines (45, 46, 62, 65, 66). Before apply-
ing Pam3Cys as adjuvant, analogs were made and their biolog-
ical activity tested. Immunological effects of Pam3Cys attached
to additional one of five further amino acids were investigated
by measuring mitogenicity toward splenocytes and the humoral
immune response against the protein conjugate bovine serum
albumin (BSA) (67). Out of the analogs (Pam3Cys-Ser-Ser-Asn-
Ala, Pam3Cys-Ser-(Lys)4, Pam3Cys-Ala-Gly, and Pam3Cys-Ser),
Pam3Cys-Ser (Lys)4 was the best. Compared to the other analogs,
Pam3Cys(Lys)4 was more soluble due to the hydrophilic lysine
residues, was a potent activator of splenocytes, and optimal for
humoral response.
The majority of Pam3Cys studies make use of diastereomeric
mixtures. Several studies have revealed that enantiopure Pam3Cys
derivatives that contained R-configured glycerol were more effec-
tive at inducing of cytokine and antibody production in mice
when administered with antigens (45, 68, 69). It is likely that
the R-configuration of the glycerol part of Pam3Cys results in
a better interaction with, or has an agonistic effect on, TLR2.
The effect of two diastereomers of Pam3Cys-Ser (Lys)4 on DCs
was investigated in a more recent study (64). The R-configured
glycerol conjugated to the ovalbumin CTL epitope led to better
activation of DCs than the S-configured glycerol as determined
by higher cytokine secretion and upregulation of DC matura-
tion markers (64). Interestingly, no difference in the uptake of the
R- and S-epimers were observed. Induction of antigen-specific
CTL cells was significantly higher in mice administered S-epimers
than mice that received the R-epimers (64). It was concluded that
enhanced DC activity was due to improved TLR2 activation by
FIGURE 5 | Schematic structure ofTLR2-targeting lipopeptides used in peptide vaccine development. (A) Pam2Cys and Pam3Cys lipidated peptide.
(B) Palmitoylated peptide (C). Lipoamino acid-based peptide.
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the S-epimers of Pam3Cys-Ser (Lys)4, resulting in enhancement
of the CTL response.
Self-assembled aggregates can function as effective immuno-
gens. Therefore, the stereochemical influence of self-assembly on
Pam3Cys and Pam3Cys-Ser were studied. The chirality of the glyc-
eryl moiety and the additional serine unit was found to influence
aggregation behavior (65). He more biologically active derivatives
contained a serine moiety which formed more thermodynamically
stable tubes or rodlike aggregates. This observation was even more
pronounced when only one of the two epimers was present.
Synthetic lipopeptide libraries have been used to characterize
the contribution of the lipid portion of Pam3Cys to TLR2 spe-
cific recognition (66, 67). The activity of Pam3Cys lipopeptides is
strongly influenced by the number and type of fatty acids present
(66). Cellular responses were abolished with single chain lipopep-
tide substitution while cytokine activity was significantly reduced
for lipopeptides carrying fatty acids with less than 10 carbon chain
length (66). Using HEK293 cells expressing recombinant human
TLR2, it was demonstrated that the two ester-bound palmitic acids
in Pam3Cys mediate a high stimulatory activity while the analog
that contained one amide-bound and one ester-bound palmitic
acid molecule was inactive (67). In addition, lipopeptide recog-
nition through both murine and human TLR2 depends on the
length of the two ester-bound fatty acid chains. These results indi-
cate the importance of the two ester-bound acyl chains rather
than the amide-bound acyl chain for TLR2 recognition, as well as
a requirement for a minimal chain length (67).
Structure-activity studies with Pam3Cys identified that addi-
tion of polar amino acids (e.g., Lys) increased mitogenicity more
than Pam3Cys alone and is preferred for use in vaccines. The length
of the fatty acid chains plays a marginal role when amide-bound.
However ester-bound fatty acid chains have a significant influ-
ence on TLR2 activation. Lipopeptides with R-configuration in
the glyceryl moiety have a higher activity than S diastereoisomers.
Toll-like receptor engagement on APC has been demonstrated
to influence both primary and secondary TH-cell responses, sug-
gesting that long-term functional capacities of TH cells are deter-
mined by innate signals during early stages of infection (70).
Induction of influenza hemagglutinin (HA)-specific naive TH cells
with HA peptide and the TLR2 agonist Pam3CysK in vivo resulted
in a high frequency of activated HA-specific TH cells (70). The
TLR2-mediated priming also led to an increased frequency of
antigen-specific memory TH cells leading to enhanced responses
to influenza challenge.
While highly immunogenic and effective at adjuvanting peptide
epitopes, lipopeptides that contain Pam3Cys have poor solubil-
ity characteristics, making dosing, and formulation difficult. This
is predominantly due to the hydrophobic moiety that results
from the lipid chains. To overcome this challenge, investiga-
tions have focused on the structurally similar derivative, S-[2,3-
bis(palmitoyloxy)propyl]cysteine (Pam2Cys) that contain one less
palmitic acid group and a free amino group with improved solu-
bility characteristics (Figure 5A). Pam2Cys is a synthetic analog of
macrophage activating lipopeptide-2 (MALP-2) derived from the
cytoplasmic membrane of Mycoplasma fermentans (69). Effective
immune responses (both antibody and/or cell-mediated) against
peptide antigens can also be successfully induced through the
use of Pam2Cys (68). Furthermore, Pam2Cys has more favor-
able solubility properties than Pam3Cys (71). It has also been
reported that Pam2Cys is a more potent stimulator of spleno-
cytes and macrophages than Pam3Cys (72–74). The structure-
activity relationship between the luteinizing hormone-releasing
hormone (LHRH) sequence, a TH epitope, and a lipid moiety
(either Pam2Cys or Pam2Cys) was investigated (71). The lipid
moiety was attached either to the N-terminus or between the TH
epitope and LHRH. The lipopeptide constructs displayed different
solubilities and immunological properties that depended not only
on the lipid moiety but also on the position of the lipids. Zeng et
al. established the most effective vaccine candidate was the most
soluble construct which contained Pam2Cys attached at the center
of the molecule (71).
Several structural details influence the activity of Pam2Cys
as measured by nitric oxide release in macrophages (75). Sim-
ilar to Pam3Cys, TLR2 was observed to discriminate between
the two PAM2Cys stereoisomers; the natural R isomer was 100
times more active than the S isomer (75). Substitution of the
free N-terminus with either an acetyl or palmitoyl group reduces
its activity (76). It was concluded that the lack of acyl moiety
in mycoplasmal lipopeptides is a key component of their excep-
tionally high macrophage stimulatory capacity (74). Removal of
either (or both) ester-bound fatty acids significantly lowered, or
abolished, specific biological activity (76). Substitution of the
two ester-bound fatty acids with amide bonds also led to abo-
lition of TLR2 agonist activity (77, 78). The influence of fatty
acid length on Pam2Cys activity was also investigated through
its ability to activate TLR2 specific cells and induce an antigen-
specific humoral response (67, 79). Experimentation in HEK293
cells that expressed recombinant human TLR2 found that the
two ester-bound fatty acid lengths should be beyond an alkyl
chain of eight carbons (67). Pam2Cys immunogenicity experi-
ments in an in vivo BALB/c mouse model found that the LHRH-
specific antibody response was dependent on the length of the
alkane chains with the order C18=C16>C12>C8 (79). There-
fore C16 appears to be the optimal chain length to promote
TLR2 recognition of Pam2Cys. In the pursuit of structurally
and synthetically simpler Pam2Cys analogs, Agnihotri et al. con-
firmed the importance of at least one acyl group of optimal
length (C16) and the appropriate orientation of the ester car-
bonyl group. The spacing between one of the palmitoyl ester
carbonyl and the thioether was crucial for hydrogen bond forma-
tion, which is important in the association between lipopeptides
and TLR2 (80).
Pam2Cys based lipopeptides have been studied to compared
the quality of cellular immunity generated after lipopeptide vacci-
nation to that observed after influenza A virus infection (81). The
number of resident memory CTL in the lungs was equivalent to
that observed after viral infection. It was further demonstrated the
Pam2Cys moiety was required for efficient expansion of mem-
ory CTLs as the CTL recalled with the unlipidated construct
was lower (81). This suggests the lipid moiety plays a part in
enhancing and maintaining immunological memory. This is fur-
ther emphasized by human T cells which express high levels of
TLR2 after activation and memory T cells express TLR2 and pro-
duce cytokines in response to bacterial lipopeptide (82). Therefore,
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TLR2 and its ligands mediate antigen-specific T cell development
and participate in the maintenance of memory T cells.
The lipopeptides illustrated in Figure 5 contain two serine
residues between the lipid moiety and the peptide epitopes. It was
demonstrated that placement of these serine residues could sig-
nificantly affect the efficacy of lipopeptides in inducing immune
response to peptide epitopes (79). To investigate whether the ser-
ine residues acted as spacers or whether they actively contributed
to the potency of Pam2Cys lipopeptides they were replaced with
another hydrophilic residue (arginine) or with the chemically
inert spacer 6-amino hexanoic acid (79). Anti-LHRH antibody
titers elicited by the lipopeptides that contained arginine or ser-
ine spacers were similar (79). In contrast, anti-LHRH antibody
titers induced by lipopeptides containing the more hydrophobic
6-amino hexanoic acid was approximately 10-fold lower. These
results suggest that instead of acting solely as spacers, the amino
acid situated between lipid and peptide contributed to the adju-
vanticity of the lipid moiety with more hydrophilic spacer being
optimal (79).
Studies investigating the development of simplified but potent
TLR ligands have been aided by the recent publication of co-
crystal structures for TLRs and their ligands. Crystal structures of
the human TLR1-TLR2-lipopeptide complex and murine TLR2-
lipopeptide complex have been published (83). Binding of the
tri-acylated Pam3Cys-Ser (Lys)4 induces the formation of an “m”
shaped heterodimer between TLR1 and TLR2 whereas binding
of the di-acylated lipopeptide, Pam2Cys-Ser (Lys)4 does not (83).
Heterodimerization of the receptors was mediated by the three
acyl chains of Pam2Cys-Ser (Lys)4 with the two ester-linked lipid
chains inside TLR2 while the amide-linked lipid chain resided in a
hydrophobic pocket in TLR1 (83). Heterodimer formation was
stabilized by hydrogen bonding and hydrophobic interactions.
It was hypothesized that formation of the TLR1 and TLR2 het-
erodimer brings the intracellular TIR domains closer, promoting
dimerization and induction of signaling (83).
Structural formulas of various Pam3cys and Pam2Cys based
lipopeptide derivatives with the main points of variation in the
fatty acids, glycerol moiety, or the cysteine residue have been
summarized in detail previously (59). With the focus on more
simplified TLR ligands, many groups have utilized simpler acyl
moieties for lipopeptide vaccine development. Acyl moieties are
more easily synthesized and incorporated into peptide antigens
than either Pam2/Pam3Cys. Two of the most studied involve the
attachment of palmitic acid and lipoamino acids (Figures 5B,C
respectively). The following section will provide information on
these most studied simple TLR2 ligands for lipopeptide vaccine
development.
PALMITIC ACID
One of the earlier studies used palmitic acid covalently attached to
a synthetic peptide from ovalbumin (Ova) to investigate the effect
of lipidation on MHC class II-restricted presentation to T cells
in vitro (84). Palmitoylated Ova was found to activate murine T
cells at lower doses than the native antigen (84). It was hypothe-
sized that the palmitoyl group directly participated in stabilizing
the peptide displayed on the MHC-TCR complex during antigen
presentation (84). These findings had implications for modulating
the immunogenicity of synthetic peptides attached to palmitic
acid (85).
Investigation of the adjuvanting activity of fatty acid esters
highlighted the role of acyl chain length and degree of satura-
tion on the humoral response to BSA and staphylococcal toxoid in
mice (86). Adjuvant activity was increased by changing the chem-
ical properties of the esters by: (i) using ethyl esters where the
acyl chain length of the fatty acid component was 16 or greater
and isobutyl and isopropyl esters of palmitic acid (C16: 0) were
superior to ethyl esters (86).
Palmitoylated peptides have been assessed as vaccine candi-
dates for numerous diseases, some of which have been evaluated
in clinical trials (87). Development on an anti-human immunod-
eficiency virus (HIV) lipopeptide vaccine used peptides derived
from regulatory or structural HIV-1 proteins (Nef, Gag, and Env)
modified by C-terminal addition of a single palmitoyl moiety (87,
88). A phase I study to evaluate immunogenicity and tolerance of
the lipopeptide vaccine in human volunteers given three injections
of the lipopeptide found that the vaccine elicited strong multiepi-
topic B and T cell responses (88). Production of immunoglobulin
G (IgG) antibodies that recognized the Nef and Gag proteins was
also observed (88).
Mapping of B and T cell epitopes has allowed the lipopeptide
vaccine approach to be extended to the most relevant epitopes
within the pre-erythrocytic stage of malaria (89). In a pre-clinical
study in chimpanzees (genetically the closest primate relative of
humans), the feasibility of a palmitoylated peptide derived from
malarial liver-stage antigen-3 targeting infected hepatocytes has
been demonstrated (90). This approach used mixtures of syn-
thetic antigens from liver-stage antigen-3 to induce protective
immunity (90).
A lipopeptide-based vaccine for human cytomegalovirus
(HCMV) that involves the lipidation of a HCMV CTL epitope
derived from the immunodominant pp65 protein linked to a uni-
versal TH epitope, induced antigen-specific CTL response (91).
These CTLs recognized, and were capable of lysing, HCMV-
infected human cells.
Induction of CTL mediated long-term influenza virus clear-
ing responses by lipopeptides had been examined (92). The
most potent immunogen for eliciting pulmonary viral clearing
responses contained peptides representing determinants for TH
and CTL peptides epitopes together with two or four palmitoyl
groups. The lipopeptides and the non-lipidated analogs induced
equivalent levels of cytolytic activity in the primary effector phase
of the response when administered with additional adjuvant.
The ability to recall lytic responses, however, diminished much
more rapidly in non-lipidated analogs. By 15 months postprim-
ing, lytic activity in lipopeptide-inoculated mice remained potent
unlike non-lipidated peptide-primed mice. The HBV-specific CTL
responses induced in humans by lipopeptide vaccination were
found to be a safe and effective means of generating significant
memory CTL responses (93). CTL responses induced were simi-
lar magnitude to patients who successfully cleared HBV infection
induced by natural exposure. Plasmodium falciparum liver-stage
antigen with the addition of a palmitoyl chain were shown to
increase immunogenicity and lead to long lasting antibody pro-
duction up to 8 months (94). B and T cell responses induced by this
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lipopeptide were reactive with native parasite protein epitopes and
was safe and highly immunogenic in chimpanzees (94), a primate
with an immune system similar to that of humans. The ability to
induce CTL responses including the magnitude, consistency, and
memory of CTL responses in chimpanzees demonstrated signif-
icant CTL responses 9 months after the final immunization (89).
The percent specific lysis had only decreased from 22.3 to 18.7% for
the best lipopeptide vaccine candidates (89). The murine influenza
virus CTL epitope NP 147–155 as a model system covalently
attached to two palmitic acids was found to be highly immuno-
genic, and a single injection resulted in memory CTL induction
that persisted for more than 1 year (95). These studies demonstrate
lipopeptides safely induce specific memory immune response in
mice and humans of such magnitude and persistence as to be of
therapeutic importance.
Mucosal administration of lipopeptide vaccines rather than
standard parenteral injections is advantageous from a safety, logis-
tical, and cost point of view (96). Furthermore, non-invasive
mucosal immunization allows the possibility to induce mucosal
immunity concurrently with systemic immunity, while systemic
immunization does not induce mucosal immunity. Lipidation is
essential in directing mucosally administered antigens across the
mucosal epithelial layer (96). The mucosal surface is the first line
of defense against many pathogens and immunity at this local
site could prevent infection before the disease develops. A her-
pes simplex virus type 2 (HSV-2) CTL epitope conjugated to a
palmitic acid moiety was delivered mucosally and generated HSV-
2-specific CTLs both locally in the genital tract and at systemic sites
(97). Thus lipopeptides as novel mucosal vaccines have attractive
practical and immunological benefits (98).
It has been established that synthetic mimics of bacterial
lipopeptides (Pam3/Pam2Cys) exert their self-adjuvanting activ-
ity through TLR2, less is known about how lipopeptide vaccine
candidates that contain palmitic acids exert their immunologi-
cal effect. These lipid components bear little structural similarity
to bacterial lipopeptides apart from the presence of an acyl moi-
ety. However, it has been shown that lipopeptides that contain a
single palmitic acid enhance uptake, maturation, and production
of pro-inflammatory cytokines release by DCs in a TLR2 spe-
cific manner (97, 99). This highlights how simpler lipid structures
may be employed for the development of TLR2-targeting peptide
vaccines.
LIPOAMINO ACID
An antibody response against peptide epitopes can be elicited by
synthesis of the epitope from lipoamino acids (LAA) (Figure 5C).
Lipoamino acids are alpha-amino acids with long hydrocarbon
side-chains that combine the structural features of lipids with
those of amino acids (100). Their ease of synthesis and the abil-
ity to modify the hydrocarbon side-chain (lipid character) makes
LAAs ideal for enhancing peptide immunogenicity.
A subsequent application of this technology has been the devel-
opment of the lipid-core peptide (LCP) system (Figure 5C), which
incorporated the lipoamino acid-based adjuvant into a polylysine
system to enhance the immunogenicity of peptides (101). Incor-
poration of two or three copies of LAAs, with glycine spacers allows
mimicry of the Pam2Cys and Pam3Cys structure.
A preliminary study with LAAs as adjuvants showed
that attachment with peptide-epitope significantly enhanced
immunogenicity (up to 3200-fold) (102). LAA were attached to
epitopes derived from the variable domains (VD) of Chlamydia
trachomatis (C. trachomatis) outer membrane protein. A high
titer antibody response was generated against three serovars of
C. trachomatis that cause trachoma (102).
The LAA-based platform has been used to immunize against
group A streptococci (GAS) (101, 103, 104), the causative agent
of rheumatic fever and rheumatic heart disease. In an extensive
structure-activity study to enhance the immunogenicity and opti-
mize the constructs to stimulate immunity against GAS M protein
specific p145 peptide epitopes, a library of different LCP constructs
were synthesized and the immunogenicity of each compound
examined (105). The most immunogenic constructs contained the
longest alkyl side-chains for the LAAs (18 carbons). The number of
copies of LAAs in the constructs affected the immunogenicity and
spacing between the LAAs increased immunogenicity. Some con-
structs without external adjuvant were more immunogenic than
the p145 peptide administered with complete Freund’s adjuvant
(CFA) (105). CFA is the gold standard for adjuvant efficacy but
restricted to animal use due to its toxicity. These data showed the
potential for LCP based lipopeptides to enhance immunogenicity
of GAS derived peptides.
Development of self-adjuvanting lipopeptide vaccine candi-
dates composed of three components: a GAS B cell epitope (J14), a
TH epitope derived from canine distemper virus, and an immuno-
stimulant based on LAA showed that the orientation of the three
components affected the J14-specific immune response (anti-
body titer) (106). Correlations between spatial arrangements of
the three components and both the vaccine secondary structure
(conformation) and level of protection against GAS infection was
identified in a later study (107).
LAA-based lipopeptide vaccine candidates have been designed,
synthesized, and immunologically evaluated for a number of other
diseases. Constructs incorporating a cluster of the most common
tumor-associated carbohydrate antigens (known as Tn antigen)
covalently attached to T cell peptide epitopes and LAA con-
sisting of two 16-carbon lipoamino acids have been evaluated
(108). These constructs induced potent antibody responses in
mice without the need for an additional adjuvant, carrier protein,
or special formulation (e.g., liposomes). Structure-activity studies
demonstrated that linear or branched vaccine architecture had a
significant effect on antibody recognition (108).
In an attempt to develop a vaccine to target the most prevalent
human hookworm, Necator americanus, a B cell peptide-epitope
from the apical enzyme in the hemoglobin digestion cascade (the
aspartic protease Na-APR-1) was incorporated into the LCP sys-
tem. The LCP construct induced a strong IgG response in mice
and antibodies produced were able to bind to and completely
inhibit the enzymatic activity of Na-APR-1 in vitro. The results
presented show that the construct can induce enzyme-neutralizing
antibodies in mice.
Evaluation of whether LAA-based lipopeptides that incorpo-
rate TH and CTL epitopes could induce epitope-specific T cell
responses and protect against pathogen challenge in a rodent
malaria model has recently been undertaken (109). The vaccine
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constructs failed to induce an expansion of antigen-specific
response. However CTL responses of unknown specificity were
induced which were able to protect against parasite challenge
(109). These data demonstrate that vaccination with LAA-based
vaccine candidates can confer non-specific protective immunity
against Plasmodium parasite challenge.
LAA-based lipopeptides have been used extensively for the
development of a mucosally active GAS vaccine (110, 111).
Immunological evaluation in mice demonstrated that the point
of epitope attachment and the length of the LAA alkyl chain
have a profound effect on vaccine immunogenicity after intranasal
administration (111). It was demonstrated that a vaccine featuring
a C-terminal lipid moiety that contained alkyl chains of 16 car-
bons; a TH epitope located at the N-terminus; and J14 attached
to the side-chain of a central lysine residue, was capable of induc-
ing optimal antibody response and mucosal IgA response (110,
111). Through structure-activity studies, a GAS vaccine candidate
that induced J14-specific mucosal and systemic antibody responses
when administered intranasally without additional adjuvants was
identified. The systemic antibodies elicited inhibited growth of
GAS in vitro (111). J14-specific mucosal antibody titers corre-
sponded with reduced throat colonization after GAS respiratory
challenge (111).
The self-adjuvanting effect of LAA-based lipopeptides was
demonstrated to act through stimulation of TLR2 and DC acti-
vation (110, 112). Investigation to determine whether LAA-based
lipopeptides activated NF-κB in a TLR2 dependent manner found
that activation was dose-dependent and affected by the length of
the alkyl chains of the incorporated lipid moieties with the hier-
archy 16 carbons> 14 carbons> 12 carbons (113). Two copies of
LAA was more effective for NF-κB activation that one or three
copies (113). To determine whether lipopeptides were recognized
by DCs in vivo, cohorts of mice were administered LCP constructs.
Splenic DCs were isolated and maturation assessed by measuring
MHC class II expression. It was found that the expression of MHC
class II increased by day 3, and that co-stimulatory molecules were
upregulated (114). It was also determined that LCP was capable of
signaling through human TLR2 in an in vitro based assay (114).
LAA-based lipid moieties have significant adjuvant activity and
are able to induce the maturation of murine DCs, potentially by
signaling via TLR2.
CONCLUSION
Peptide-based vaccines offer several advantages over the conven-
tional vaccines in terms of purity and specificity of the immune
response elicited. However, the use of often toxic adjuvants, which
are critical for immunogenicity of synthetic peptides, have ham-
pered their progress. Improvements in immunogenicity through
lipidation of peptides discovered several decades ago is a promis-
ing approach. Several pre-clinical and clinical trials have revealed
that lipopeptide vaccines are effective, safe, and can be synthe-
sized based on minimal peptide epitopes using peptide synthesis
methods to combat wide variety of infectious diseases.
More recent scientific advances have identified mechanism
that lipopeptide self-adjuvanting activity occurs through the PRR
TLR2. Mammalian TLRs are expressed on macrophages and DCs
which are primarily involved in mediating immune responses.
TLRs are critical for sensing invading pathogens and recog-
nition by TLRs provokes rapid activation of innate immunity
through induction of inflammatory cytokines and upregulation
of co-stimulatory molecules. This subsequently leads to effective
immunity. In this regard, TLRs are adjuvant receptors and have
allowed the development of promising lipopeptide vaccine candi-
dates. Rational vaccine design, including optimization of immune
response through structure-activity studies, allows the elicitation
of predictable immune responses to combat pathogens. In par-
ticular, the recent mucosal application of lipopeptide vaccines
represents an ideal strategy against many pathogens as the mucosal
surfaces represents a primary infection site. Using non-invasive
mucosal routes would be highly advantageous for vaccination pro-
grams, since mucosal administration is simple, needle-free, and
cheap.
With our recent understanding of how the lipid component
confers the “self-adjuvanting” activity of lipopeptides and the
development of simple lipid moieties, lipopeptide could form the
basis for vaccine development against numerous diseases.
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